insights_auto
Nega 6160 oshdi 4,36%?
Batafsil oʻrganishchevron_right
6160:HKG
BeOne Medicines AG
225,00 HK$
arrow_upward
+4,36%(+9,40) 1K
16-okt, 16:08:14 (GMT+8) · HKD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto6160 tikeri uchun statistika yaratilmoqda...
Ochish
224,80 HK$
Yuqori
230,20 HK$
Past
221,80 HK$
Bozor kapitali
355,76 mlrd
Oʻrtacha hajm
2,93 mln
Hajmi
4,41 mln
P/E koeffitsiyenti
65,67
52 haftalik eng yuqori
235,60 HK$
52 haftalik eng past
153,00 HK$
Aksiya boʻyicha daromad
3,43 HK$
Muomaladagi aksiyalar
1,43 mlrd
Xodimlar soni
12 ming
Ochish
224,80 HK$
Yuqori
230,20 HK$
Past
221,80 HK$
Bozor kapitali
355,76 mlrd
Oʻrtacha hajm
2,93 mln
Hajmi
4,41 mln
P/E koeffitsiyenti
65,67
52 haftalik eng yuqori
235,60 HK$
52 haftalik eng past
153,00 HK$
Aksiya boʻyicha daromad
3,43 HK$
Muomaladagi aksiyalar
1,43 mlrd
Xodimlar soni
12 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
MarketBeat
·
3 kun oldin
BeOne Medicines (NASDAQ:ONC) Stock: Insider Xiaodong Wang Sells 31,027 Shares
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
BeOne Medicines AG haqida
CEOJohn Vincent Oyler | John Vincent Oyler
Xodimlar soni12 ming
Asos solingan28-okt, 2010
Bosh ofislar-
Sektor-
Veb-saytbeonemedicines.com